HERBERT研究:直肠癌老年患者外照射联合腔内近距离放疗的临床与内镜毒性评估
HERBERT研究在38例不可手术/老年T2-T4N0-1直肠癌患者中评估EERT后高剂量率腔内近距离放疗加强的毒性。患者接受13×3 Gy EBRT后每周三次HDREBT(5-8 Gy)。患者报告肠道症状在EBRT结束时和HDREBT后两周明显增加,急性2级和3级直肠炎分别占68.4%和13.2%,晚期2级和≥3级直肠炎分别占48%和40%。
要点
- 急性2级和3级直肠炎发生率分别为68.4%和13.2%。
- 晚期2级和≥3级直肠炎发生率分别为48%和40%。
- 最严重毒性多出现在治疗后12-18个月。
核心结论
- 对老年直肠癌患者,根治性放疗可获得良好肿瘤反应但毒性风险显著。
- HDREBT加强相比单纯EBRT的潜在获益与风险须进一步评估。
研究设计与样本
- HERBERT研究为近距离放疗剂量探索研究,纳入38例不可手术/老年T2-T4N0-1直肠癌患者。
- 患者接受EBRT(13×3 Gy)后行三次每周HDREBT(5-8 Gy)。
- 毒性通过患者报告、医师报告(CTCAEv3)及内镜三种方法评估。
- 统计采用Wilcoxon符号秩检验、配对t检验和Spearman相关分析。
主要发现
- 患者报告肠道症状在EBRT结束时和HDREBT后两周明显增加。
- 急性2级和3级直肠炎分别占68.4%和13.2%。
- 晚期2级和≥3级直肠炎分别占48%和40%。
- 内镜评估主要显示红斑和毛细血管扩张,3例患者出现明显出血或溃疡。
- 最严重毒性观察于治疗后12-18个月。
临床怎么用
- 对不可手术/老年直肠癌患者行根治性放疗时,应充分告知患者显著的直肠毒性风险。
- 治疗后12-18个月应重点监测晚期毒性,并结合患者报告、医师评估及内镜综合判断。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The HERBERT study evaluated a high-dose-rate endorectal brachytherapy boost (HDREBT) after EBRT in medically inoperable/elderly patients with rectal cancer. The response-rates are promising but not without risk of toxicity. The current analysis provides a comprehensive overview of patient reported, physician reported and endoscopically observed toxicity. MATERIAL AND METHODS: A brachytherapy dose finding study was performed in 38 inoperable/elderly patients with T2-T4N0-1 rectal cancer. Patients received EBRT (13 × 3 Gy) followed by three weekly HDREBT applications (5-8 Gy). Toxicity was assessed via three methods: patient and physician (CTCAEv3) reported rectal symptoms and endoscopically. Wilcoxon's signed rank test, paired t-test and Spearman's correlation were used. RESULTS: Patient reported bowel symptoms showed a marked increase at the end of EBRT and two weeks after HDREBT. Acute grade 2 and 3 proctitis occurred in 68.4% and 13.2% respectively while late grade 2 and ≥3 proctitis occurred in 48% and 40%. Endoscopic evaluation mainly showed erythema and telangiectasia. In three patients frank haemorrhage or ulceration occurred. Most severe toxicity was observed 12-18 months after treatment. CONCLUSION: For elderly patients with rectal cancer, definitive radiotherapy can provide good tumour response but has a substantial risk of toxicity. The potential benefit and risks of a HDREBT boost above EBRT alone must be further evaluated.
引用
- Rijkmans EC, van Triest B, Nout RA, et al. Evaluation of clinical and endoscopic toxicity after external beam radiotherapy and endorectal brachytherapy in elderly patients with rectal cancer treated in the HERBERT study. Radiother Oncol. 2018. PMID: 29398154. doi:10.1016/j.radonc.2017.12.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。